Highest-materiality recent filing
Puma Biotech Q2 net income $8.2M, raises 2026 guidance on NERLYNX demand
Q2 product revenue $53.6M (+9% YoY); GAAP net income $8.2M ($0.16/sh) vs $5.9M ($0.12/sh) in Q2 2025.
Puma Biotech Q1 net loss $3.8M; raises 2026 revenue and net income guidance on NERLYNX demand
Q1 product revenue $42.0M vs $43.1M YoY; GAAP net loss $3.8M ($0.07/share) vs net income $3.0M.
Puma Biotechnology Q4 2025 revenue $75.5M, GAAP net income $13.4M; guides FY2026 net income $10-13M
Q4 2025 product revenue $59.9M (+10% YoY); total revenue $75.5M vs $59.1M YoY including $15.6M royalty.
Puma raises 2025 guidance; Q3 GAAP net income $8.8M vs $20.3M YoY on lower royalty revenue
Q3 GAAP net income $8.8M ($0.17 diluted) vs $20.3M ($0.41) YoY; non-GAAP adj. net income $10.5M ($0.21) vs $22.4M ($0.46).
Puma Biotechnology Q2 net income $5.9M vs year-ago loss; revenue rises to $52.4M
GAAP EPS $0.12 vs $(0.09) loss; adjusted EPS $0.15 vs $(0.05) loss.
Puma swings to Q1 profit; NERLYNX revenue up 7% to $43.1M
GAAP net income $3.0M ($0.06 EPS) vs net loss $4.8M ($0.10 loss) in Q1 2024.
Puma Biotechnology reports Q4 GAAP net income $19.3M ($0.39 EPS); guides FY2025 net income $23-28M
Q4 product revenue net $54.4M (up from $53.2M YoY); full year $195.2M (down from $203.1M).
Puma Biotech Q3 net income $20.3M vs $5.8M YoY; raises FY 2024 guidance
Product revenue $56.1M (+8.7% YoY); total revenue $80.5M including $24.4M royalty revenue.
Puma reports judge invalidated Tagrisso patents; Wyeth appeals Sept 12
Jury awarded $107.5M for past infringement of '314 and '162 patents through Dec 2023.
Court invalidates Puma's patents in Tagrisso suit, overturns $107.5M jury award
Jury found Tagrisso infringed Puma's patents, awarded $107.5M in damages.
Puma Biotechnology wins patent suit vs AstraZeneca; $107.5M jury award upheld in bench trial
Jury found Tagrisso infringes Wyeth's patents; damages of $107.5M for past infringement through Dec 31, 2023.
Puma Q2 NERLYNX revenue $44.4M (-14% YoY); GAAP net loss $4.5M vs profit $2.1M
Q2 2024 product revenue $44.4M (down from $51.6M in Q2 2023); total revenue $47.1M incl $2.7M royalties.
Jury awards Puma/Wyeth $107.5M in Tagrisso patent infringement case vs AstraZeneca
Jury found '314 and '162 patents infringed and not invalid; damages $107.5M for past acts.
Puma Biotech Q1 net loss $4.8M vs prior year net income; NERLYNX revenue down 14%
Net product revenue $40.3M (Q1 2023: $46.8M); total revenue $43.8M including $3.5M royalties.
Puma partially dismissed as plaintiff in Tagrisso patent suit; trial set May 13
Court denied AstraZeneca's motions for patent invalidity and summary judgment of non-infringement.
Puma Biotechnology reports Q4 GAAP net income of $12.3M; guides Q1 2024 net loss of $10-12M
Product revenue net Q4 $53.2M (flat YoY); full year $203.1M, up from $200.0M.
Puma Biotechnology Q3 2023 net income $5.8M, reverses prior-year loss; revenue $56.1M
Product revenue net $51.6M (down 5% YoY from $54.3M); total revenue $56.1M.
Puma Biotechnology Q2 net income $2.1M, down from $9.4M YoY; revenue flat at $51.6M
GAAP net income $2.1M ($0.05/diluted share) vs $9.4M ($0.21) Q2 2022; non-GAAP adj net income $4.6M ($0.10).
Puma Biotech Q1 net income $1.4M vs loss; NERLYNX revenue $46.8M (+15% YoY)
GAAP net income $1.4M ($0.03/diluted share) vs net loss of $3.4M in Q1 2022.
Puma Biotech Q4 net loss $5.6M; FY net income $0; guides FY2023 product rev $205-210M
Q4 product revenue $53.7M (+5% YoY); full year $200.0M (+6% YoY).
Puma settles Neratinib patent litigation with Sandoz; generic entry allowed Dec 2030
Settlement and License Agreement with Sandoz fully resolves pending Hatch-Waxman litigation in New Jersey.
Puma presents Phase II TBCRC-022 data: neratinib+T-DM1 achieves CNS ORR 28-33% in HER2+ BCBM
CNS objective response rate by RANO-BM: 33.3% (cohort 4A), 29.4% (4B), 28.6% (4C).
Puma Biotechnology settles defamation lawsuit for $16M; payments due in 2023 and 2024
Settlement with Dr. Fredric Eshelman for $16M resolves defamation lawsuit; no admission of liability.
Puma Biotechnology Q3 net loss narrows to $0.4M; raises FY 2022 NERLYNX revenue guidance
Q3 product revenue $54.3M, up 25% YoY from $43.4M; net loss $0.4M ($0.01/share) vs $44.7M loss in Q3 2021.
Puma Biotechnology licenses alisertib from Takeda; $7M upfront, up to $287.3M in milestones
Entered exclusive global license for alisertib from Takeda; upfront payment of $7 million.
Puma Biotech swings to Q2 profit of $0.21/sh; NERLYNX revenue up 5%
GAAP net income $9.4M ($0.21 per share) vs net loss of $5.1M ($0.13 loss) in Q2 2021.
Puma Biotechnology Q1 net loss $3.4M, product revenue down 11% to $40.7M
GAAP net loss of $3.4M ($0.08 per share) vs net income of $16.5M ($0.41) in Q1 2021.
Puma Q4 net income $4.2M vs loss; FY loss narrows to $29.1M from $60.0M
Q4 product revenue $51.0M (+2% YoY); total revenue $55.4M including $1.5M license and $2.9M royalty.
Puma Biotechnology Q3 net loss widens to $44.7M; product revenue falls 12%
Q3 product revenue $43.4M, down from $49.3M YoY; COVID-19 impact and inventory reduction of ~$3.5M.
Puma Biotech Q2 2021 GAAP net loss $5.1M vs prior-year profit; NERLYNX flat at $48.9M
GAAP net loss of $5.1M ($0.13 loss/share) vs net income of $3.4M in Q2 2020.
On May 8, 2025, Puma Biotechnology, Inc. (the “Company”) terminated Jeff J. Ludwig as an employee and as its Chief Commercial Officer.
On July 29, 2022, Alessandra Cesano, 62, was appointed to the Board of Directors (the “Board”) of Puma Biotechnology, Inc. (the “Company”), effective July 29, 2022.
On December 9, 2021, Ann Miller notified Puma Biotechnology, Inc. ("Puma" or the "Company") of her decision to resign as a director of the Company, effective December 31, 2021.
On July 8, 2021, Allison Dorval, 45, was appointed to the Board of Directors (the “Board”) of Puma Biotechnology, Inc. (the “Company”), effective July 15, 2021.
Max materiality 0.85 · Median 0.65 · Most common event earnings